Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3016 in Chinese Patients With Mild to Moderate Hypertension
NCT07556796Phase 1Active, not recruiting
- Sponsor
- Innovent Biologics
- Start
- May 2026
- Primary completion
- Oct 2027
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IBI3016 in hypertension (HTN) (5 arms), sponsored by Innovent Biologics. Primary endpoint: Number of Participants with Adverse Events at 12 weeks. Started May 2026; status: active, not recruiting.
02
Drugs
IBI3016
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT07556796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07556796.